One Year Later: Pfizer Update on Progress of Humanitarian Assistance Program
In November 2016, Pfizer Inc. announced a major expansion of its humanitarian assistance program enabling broader access to its pneumococcal conjugate vaccine (PCV) in humanitarian emergency settings. During the year since, the Company has made important progress on a number of fronts to support access.
In January 2017, our multi dose vial (MDV) of PCV became available in the world's poorest countries through our partnership with Gavi, the Vaccine Alliance. It has also been used to vaccinate children in refugee settings. This four-in-one vial addresses the unique conditions and challenges experienced in developing world settings and can help health workers in humanitarian emergencies. The MDV, which has been qualified by the World Health Organization, has cold storage and transportation efficiencies, helping to enable vaccination of more children with fewer vials. Prior to the availability of the MDV, Pfizer donated its single-dose vial to multiple partners in order to quickly help vaccinate those in unfortunate humanitarian emergencies as.
Pfizer continues to build upon its longstanding support for humanitarian emergency relief around the world. MSF International (Doctors without Borders) and Pfizer have entered into an agreement for Pfizer to supply its (PCV) for people living in humanitarian emergencies and in support of select developing country supplemental immunization activities. This multi-year agreement provides for Pfizer's supply of up to a specified volume of its PCV through December 31, 2020 with the possibility to extend for additional years. As part of Pfizer's humanitarian assistance program, the proceeds from its PCV sales to humanitarian organizations in support of humanitarian emergencies through December 31, 2017 will be donated to organizations supporting the refugee crisis.
Pfizer is providing its new MDV at the lowest prevailing global price, $2.95 per dose, for both humanitarian emergencies and Gavi countries. Pfizer also committed to extend the price of $2.95 per dose to Gavi eligible countries even after they graduate based on their improved economic standing through 2025.
In the world's poorest countries, Pfizer partners with Gavi to make its pneumococcal conjugate vaccine available to Gavi-eligible countries, which consist of 73 countries with Gross National Income (GNI)/capita of $1580 or less. Pfizer is proud of its significant commitment to the world's poorest countries. Today, one out of every two doses of pneumococcal conjugate vaccine that Pfizer distributes goes to the world's poorest countries through its Gavi partnership. To date, Pfizer has delivered more than 325 million doses of its pneumococcal conjugate vaccine helping to protect more than 29 million babies in Gavi countries each year.
Building on our commitment to supply up to 740 million doses of our PCV through 2025, via our partnership with Gavi, Pfizer also provides support for programs and disease awareness. In Niger, Mali, and the Democratic Republic of Congo, Pfizer supports health care worker training intended to help people recognize the early signs of pneumonia and inform caregivers of the importance of vaccination. Plans are in place to extend this training to Angola. In addition, the Pfizer Foundation* supports several programs aimed at increasing access to, and the quality of, immunizations and other health interventions. These important child health and survival programs are in several countries in sub-Saharan Africa, including Ethiopia, Uganda, Malawi, Kenya, and Benin.
Pfizer Humanitarian Assistance Programs
Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three-part approach which includes product donations, cash grants and other access solutions.
- Pfizer donations are focused on specific diseases and designed to address the needs of people in a coordinated manner. The Company works with a range of local and global partners, including governments, health care experts, and CSOs to address the most pressing unmet medical needs and determine the most effective way for a donation to meet the needs of affected communities.
- Pfizer supports a number of organizations working on providing relief and emergency humanitarian assistance to address refugee crises. The Pfizer Foundation provides cash grants to organizations working around the world to provide health care and other critical support to vulnerable populations.
- Pfizer works closely with governments and CSOs to help provide access to its vaccines and regularly engages in discussions with partners on potential new access approaches to reach as many people as possible in emergency humanitarian situations.
For more information on Pfizer's Humanitarian Assistance Programs please visit http://www.pfizer.com/responsibility/global-health/relief-and-emergency-humanitarian-assistance
*The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity with distinct legal restrictions.
09.22.2023 Diseases & Conditions Diversity & Inclusion Health Equity Patient Centricity Rare Diseases Sickle Cell Disease An Open Letter in Support of Sickle Cell Disease Communities 09.20.2023 Cancer Health Literacy Leadership Patient Centricity Patient-Friendly Health Literacy Resources for Cancer Patients and Caregivers 09.14.2023 Covid-19 Diseases & Conditions Vaccines Wellness This Season’s COVID-19 Vaccine Rolls Outs Across U.S. 09.07.2023 Diseases & Conditions Investments Research Advancing Metabolic Research in NASH, Obesity, and Cachexia Through Pfizer’s ASPIRE Program 09.07.2023 Vaccines Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate